Non-alcoholic fatty liver disease (NAFLD) can manifest as non-alcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH). NASH is often associated with progressive fibrosis which can lead to cirrhosis and hepatocellular carcinoma (HCC). NASH is increasing as an aetiology for end-stage liver disease as well as HCC. There are currently no approved therapies for NASH. A major barrier to development of therapeutics for NASH is the lack of preclinical models of disease that are appropriately validated to represent the biology and outcomes of human disease. Many in vitro and animal models have been developed. In vitro models do not fully capture the hepatic and extrahepatic milieu of human NASH and large animal models are expensive and logistically difficult to use. Therefore, there is considerable interest in the development and validation of mouse models for NAFLD, including NASH. Several models based on varying genetic or dietary manipulations have been developed. However, the majority do not recreate steatohepatitis, strictly defined as the presence of hepatocellular ballooning with or without Mallory-Denk bodies, accompanied by inflammation in the presence of macrovesicular steatosis. Others lack validation against human disease. Herein, we describe the best practices in development of mouse models of NASH. We further review existing models and the literature supporting their use as a surrogate for human disease. Finally, data on models to evaluate protective genes are discussed. It is hoped that this review will provide guidance for the interpretation of data derived from mouse models and also for the development and validation of newer models. Ó
Introduction
Non-alcoholic fatty liver disease (NAFLD) has emerged as a major cause of chronic liver disease in many parts of the world. 1 It has two principal clinical-histological phenotypes, namely nonalcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). NAFLD is associated with increased cardiovascular, cancer-and liverrelated mortality. 2 Liver-related outcomes are mainly due to the progression of the disease to cirrhosis. 3 It is anticipated that because of the ongoing increases in obesity and type 2 diabetes, the two principal risk factors for NAFLD, the burden of NASH will increase over the next two decades. 4 With an ageing population and increased duration of exposure to the disease, it is of particular concern that the prevalence of cirrhosis and endstage liver disease is very likely to increase unless public health measures, to check the burden of disease, are put in place. Not only is there a lack of widely implemented primary prevention strategies for NASH and its associated co-morbidities, but there is also no approved drug therapy for NASH. This underscores the importance of developing pathways to accelerate development of preventive and therapeutic strategies for NASH.
Many compounds are currently being tested for NASH. Unfortunately, none of the trials reported to date have demonstrated a dramatic improvement in disease status and many compounds have failed to show an improvement. A potential method to improve the probability of success in clinical trials is to develop robust preclinical models of the disease that are translatable to human disease. Such models would enable the testing of many compounds for evidence of efficacy before going into clinical trials. They could also be used to identify novel targets and test the impact of engaging specific combinations of molecular targets to improve the outcomes of NASH. Herein, we will focus on preclinical animal models of NAFLD with a specific focus on their translatability to the human disease.
Properties of an ideal animal model of NAFLD
The ideal characteristics of an animal model of NAFLD depend on what it will be used for. If the objective is to enhance the likelihood that a drug that improves NAFLD in the animal also improves the disease in humans, then it is imperative that the model studied mimics human disease as closely as possible (Table 1) .
It is obvious that a non-human species will never be identical to humans. However, animal models should mimic human disease with respect to its development by diet-induced obesity, the most common risk factor for the disease in humans. 5 Importantly, the dietary composition should broadly resemble human diets in terms of their macronutrient composition and not contain un-natural toxins, such as very high levels of cholesterol or di-ethylnitrosamine. Animal models should develop obesity, insulin resistance and features of systemic inflammation seen in humans with insulin resistance. 6 They should also recapitulate the systemic metabolic and inflammatory milieu, by development of dyslipidemia and increases in inflammatory cytokines such as tumor necrosis factor-a (TNF-a), interleukin (IL)-6 and a decrease in adiponectin. Furthermore, models should develop a hepatic phenotype that resembles human disease by having predominantly macrovesicular steatosis, lobular inflammation, hepatocellular ballooning (ideally with Mallory-Denk bodies) and hepatic fibrosis. 7 The lesions should be mostly centrilobular or panacinar and the fibrosis should be perisinusoidal in nature and start in zone III, as seen in humans, before progressing through portal and sinusoidal fibrosis to bridging fibrosis and nodule formation. Finally, once advanced fibrosis develops, the model should have an increased propensity for development of HCC.
Relevant models of NAFLD should not only recapitulate the diet, systemic milieu and histological spectrum of the disease, but also demonstrate activation of the key cellular pathways known to be associated with human disease, such as activation of de novo lipogenesis and the unfolded protein response. 7 Additionally, other pathogenic elements such as oxidative stress, apoptosis and fibrogenic pathways relevant to human disease should be activated. Finally, transcriptomic analyses should be able to demonstrate that there is a broad concordance between the human and mouse transcriptomic signature at various phases of disease development, which should be further reflected in the metabolome. In addition to these criteria, the models should be reproducible and the data in the model repeatable. Robustness, in terms of sensitivity to light-dark cycles, housing conditions, and ambient temperature should all be considered when selecting a specific model. 8 Below, we will critically review the existing models and identify where they do or do not meet these criteria (Table 1) .
Dietary animal models of NASH
Diet, dietary patterns, and various types of highcalorie nutrients are the important regulators and contributors of many diseases including the development, progression, and treatment of NAFLD, metabolic syndrome and cancers. 9 The animal models of NASH are mainly based on
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various types of diet, such as high-fat, highglucose, sucrose, fructose, methionine and choline-deficient (MCD) diet, choline-deficient Lamino-defined (CDAA) diet, high-cholesterol diet (HCD), cholesterol and cholate. Even in the genetic animal models of NASH, diet is used as a secondary trigger for disease progression. 7, [10] [11] [12] These diets are provided individually or in combination to induce simple steatosis and steatohepatitis.
Methionine and choline-deficient diet
The MCD diet is one of the very commonly used diets which produces the most severe phenotype of NASH in the shortest time. This diet, with high sucrose (40%) and 10% fat, but deficient in methionine and choline has been used for over 40 years and is known to very quickly induce measurable hallmarks of NAFLD, such as hepatic steatosis (mainly macrovesicular) in mice and rats by 2-4 weeks, which progress to inflammation and fibrosis shortly thereafter. 13, 14 In addition, the MCD diet alters glucose metabolism without causing insulin resistance, affects hepatic lipid metabolism with a significant increase in fatty acid uptake and reduction in very-low-density lipoprotein secretion, and induces significant fibrosis compared to other dietary animal models. [15] [16] [17] Although the MCD model replicates the histological phenotype of human NASH in a relatively short period, the associated weight loss and lack of systemic insulin resistance makes it quite different from human NAFLD. Thus, the use of the MCD model is limited by its disparity with the metabolic parameters of human NASH. Importantly, there is poor concordance between differentially expressed genes in this model and human NASH. 18 Choline-deficient L-amino-defined diet The choline-deficient, L-amino acid-defined (CDAA) dietary model is another model that develops steatohepatitis, liver fibrosis and hepatocarcinogenesis. [19] [20] [21] Similar to the MCD diet, the CDAA diet increases lipid synthesis, inflammation and causes liver injury. In addition, mice on the CDAA diet do not gain weight and do not display insulin resistance. [22] [23] [24] Hence mice on the CDAA diet display a metabolic profile that is different to human NASH. Therefore, this model is unsuitable as a surrogate for human disease. 25, 26 High-cholesterol diet Many foods contain high levels of cholesterol, particularly in Western diets. Recent studies strongly suggest that dietary cholesterol is a critical factor in the progression of steatohepatitis and hepatic inflammation, not only in animal models [27] [28] [29] but also in humans. 30 Mice fed an HCD (1%) alone show strikingly increased serum insulin levels, with only slight increases in liver weight, triglyceride levels, FFA levels, and serum alanine aminotransferase levels. 30, 31 Several studies have proven that features of NASH are not pronounced with the use of HCD in isolation. [30] [31] [32] Importantly, this level of dietary cholesterol is virtually never seen in humans with NAFLD.
Cholesterol and cholate
Cholesterol and cholate are known for their atherogenic (1.25% cholesterol and 0.5% cholate) properties. Cholic acid is a primary bile acid and is chemically known as 3a, 7a, 12a-trihydroxy-5 b-cholan-24-oic acid. The salt of cholic acid is cholate. As previously noted, this level of dietary cholesterol is not seen in most humans with obesity. Together, cholesterol and cholate induce important features of human NASH, including progressive development of steatosis, inflammation, and fibrosis with hepatocellular ballooning, in a time-dependent manner over 6-24 weeks. Along with the cholesterol and cholate diet, addition of 60% fat (cocoa butter) resulted in accelerated development of NASH features and formation of hepatocellular ballooning after approximately 12 weeks. 27 This diet also induces dyslipidemia, lipid peroxidation and oxidative stress leading to liver injury. Mice on the HCD combined with high fat and high cholate are known to display more pronounced features of NASH, but the major drawback of this combination is that mice were systematically insulin sensitive, lost 9% of their body weight and developed small epididymal fat pads, whilst exhibiting low plasma triglyceride levels compared to control mice. 33 Therefore, even though this diet replicates human disease pathology, the diet is not relevant to the human state and the metabolic status differs from human NASH.
High-fat diet (HFD)
Rats fed an HFD composed of 71% fat, 11% carbohydrates, and 18% proteins for three weeks are known to develop insulin resistance with marked panlobular steatosis, inflammation and fibrosis. 7, [10] [11] [12] Whilst mice fed with HFD showed similar results to rats they took more time to develop NASH features (around 16 weeks). Thus, the key feature of this model is that the results vary with rodent strain and the composition of the diet. 34 The model displays NASH features similar to human NASH, but the pathological outcome is not as severe, limiting the use of this model. The C57Bl6/J mice are more insulin resistant and thus more likely to be relevant than the C57Bl6/N mice. 35 High-fructose diet High consumption of fructose rich foods has been associated with the development of obesity and NASH. 36 Findings from various studies with C57BL/6 mice fed an HFD or high-fat, highfructose (HFHF) diet suggest that fructose consumption is necessary for the development and progression of liver fat deposition to fibrogenesis
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(NAFL to NASH). It is interesting to note that when compared to mice fed with HFD, the mice fed an HFHF diet had increased hepatic inflammation, oxidative stress and fibrosis. 36, 37 The use of a high-fat, -fructose and -cholesterol (FFC) diet composed of 40% fat, 42 g/L final concentration fructose and 0.2% cholesterol recapitulated the features of insulin resistance, steatosis, inflammation with hepatocellular ballooning and progressive fibrosis. 38 The FFC model further mimicked human NASH, displaying the interrelationship between inflammation in both liver and adipose tissue. 38, 11 Thus, the addition of fructose to a high-fat diet promotes the development of hepatocellular ballooning with increased inflammasome activation and fibrosis in the mouse models of NASH. However, in a C57Bl6/J mouse, a high-fat diet with fructose does not consistently progress to advanced fibrosis or HCC. Notably, a high-fructose diet alone, when administered ad libitum, does not produce a hepatic phenotype of NASH.
38,39
The streptozotocin high-fat diet model In this model, C57Bl6/J mice were give streptozotocin (200 lg) two days after birth. Surviving mice were then started on a high-fat diet. 40 These mice develop steatohepatitis, fibrosis and HCCs in approximately 20 weeks. 40 This model recapitulates several important histological aspects of human NAFLD and is also associated with oxidative stress, 41 but differs from the human state as beta cell function loss is induced by streptozotocin rather than a systemic, inflammatory, insulin resistant mileu. However, in a similar model where mice were given streptozotocin followed by a high-fat diet, investigators failed to demonstrate concordance between mice and humans. with respect to differentially expressed genes. 42 The diet-induced animal model of NAFLD (DIAMOND) The limitations of existing models led us to develop a mouse model of NAFLD that meets many criteria for a relevant NASH model outlined above. 7 It is based on an inbred isogenic strain of a C57Bl6/J and S129S1/svlmJ mice, where approximately 60% of genes are from the C57Bl6/J background based on a panel of single nucleotide polymorphisms from the Jackson Laboratory. Importantly, the isogenic nature of the mice has been confirmed across multiple generations and the phenotype of the disease has been maintained by careful attention to the breeding protocol over 20 generations. Under conditions of a chow diet, the mice retain normal weight and have a normal life span. However, upon starting a high-fat, highcarbohydrate diet (Western diet [WD]) with 42% Kcal from fat and 0.1% cholesterol, as well as ad lib administration of glucose/fructose (sugar water, 23.1 g/L d-fructose + 18.9 g/L d-glucose) in drinking water, the mice recapitulate human NAFLD by developing obesity, insulin resistance, dyslipidemia and sequentially fatty liver, then steatohepatitis, followed by stage 1 fibrosis, which progresses to early nodule formation (stage 3 and early stage 4 fibrosis) and HCC when advanced fibrosis is present. Importantly, there is true steatohepatitis with hepatocellular ballooning and Mallory-Denk bodies, as well as clearing of cytoplasmic CK18, not simply steatosis and inflammation (Fig. 1) . 7, 43 The fibrosis also progresses in a manner similar to that in humans (Fig. 2) . Adipose tissue inflammation and hypoadiponectinemia also develop, as seen in humans. Furthermore, the key pathways activated in human NAFLD are also activated in this model, along with oxidative stress, the unfolded protein response, inflammatory, apoptotic and fibrogenic pathways. 7, 44 In contrast to data from the MCD model, the HFD with streptozotocin and the PTEN genetic models, there is a strong concordance with the human NAFLD transcriptome throughout the various stages of disease development; these data have been deposited in the NIH database. 7 This model recreates many of the key features of human disease.
The principal differences between the DIA-MOND mice and human disease include suppression of cholesterol synthesis and the high frequency of HCC development in the DIAMOND
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DIAMOND mice Human NASH

Steatosis
Hepatocyte ballooning Lobular inflammation mice. However, the HCC are similar to human HCC with respect to the molecular gene signatures. 7, 45 Another limitation is that it takes up to 16 weeks to develop steatohepatitis. Moreover, fibrosis develops and progresses to bridging fibrosis/early cirrhosis over 36 weeks from initiation of the diet. A potential limitation is difficulty breeding knockout or overexpressing mice into the mixed background of the DIAMOND mice.
The Ossabaw pig model of NAFLD This animal has been shown to develop obesity, insulin resistance and hepatic phenotypes like those seen in humans, along with fibrosis. 46 The principal limitations of this model are the cost and logistical challenges of using pigs as preclinical models of human NAFLD.
Genetic animal models of NASH
With the advances in genetic engineering, it has been possible to create various experimental rodent models. The nature of the specific gene alteration needed renders these mice different from humans, who do not have these specific genes altered. However, such models are particularly valuable for the study of specific pathways and the mechanisms by which they may alter metabolic homeostasis in the liver, including the consequences of such dysregulation. Modified diets are frequently required to induce the histopathological and biochemical changes of NASH in these mice.
Leptin deficiency (ob/ob mice)
Leptin is a peptide hormone secreted predominantly by adipocytes of white adipose tissue and plays a vital role in the regulation of energy balance. The ob/ob mice lack functional leptin and they easily develop severe insulin resistance. 47, 48 In ob/ob mice fat is redistributed from adipose tissue to the liver and other non-adipose tissues, due to the deficiency of this hormone. This results in the accumulation of fat in the liver, which further induces hepatocyte lipotoxicity and lipoapoptosis. However, ob/ob mice rarely develop NASH, which may be because of alterations in inflammatory responses and other effects. 49 Also, leptin deficiency requires an additional stimulus (LPS, HFD, MCD etc.) to induce features of NASH. In addition, it is also known that ob/ob mice are resistant to hepatic fibrosis. Leptin mutations have been reported in humans, but clinical studies have shown that serum leptin levels are normal or elevated in NAFL and NASH patients compared to healthy controls. 50, 51 Thus ob/ob mice models have limited use for the study of NASH.
Leptin receptor deficiency (db/db mice) db/db mice or leptin receptor deficient mice carry a point mutation in one of the leptin receptor genes, which leads to defective leptin signaling. The phenotype of db/db mice is very much like ob/ob mice and although these mice have normal or elevated leptin levels, they are resistant to the effects of leptin. The db/db mice also have abnormally increased appetite and develop obesity, hyperglycemia, hyperinsulinemia, insulin resistance and fatty liver. 11, 52 The db/db mice show the features of NASH with additional stimuli, such as high-calorie diet or MCD. 53 Unlike ob/ob mice, db/db mice develop fibrosis when fed with MCD. 53, 54, 15, 16 Their ability to develop advanced fibrosis and HCC is not well characterised.
db/db mice supplemented with iron Along with HFD, high-calorie diet and MCD diet, a recent report showed that iron overload in db/db mice also causes progression of simple steatosis to steatohepatitis and fibrosis. 55 Iron deposition may take place at a subcellular location in hepatocytes, sinusoidal lining cells and the reticuloendothelial system. Chow diet supplemented with a high iron load also induced major NAFLD features, such as hepatocellular ballooning, hepatic inflammatory immune cell activation, increased hepatic oxidative stress and impaired hepatic mitochondrial fatty acid b-oxidation and fibrogenesis in db/db mice. 55, 31 Thus, iron may potentiate the development and progression of NAFLD via various mechanisms such as oxidative stress, altered insulin signaling or lipid metabolism. 56 However, the development of NAFLD with a chow diet raises concerns about the translatability of this model. foz/foz mice Alstrom syndrome 1 or ALMS1 is a protein which in humans is encoded by the ALMS1 gene. Alms1 is a ubiquitous protein which is essential for proper primary cilia function. Although this gene function has not been fully studied and elucidated, it may have a very important role in intracellular transport and appetite regulation. Mice which are mutated or deficient in Alms1 are called foz/foz mice. Like ob/ob and db/db mice, these mice are also obese, insulin resistant and display steatosis. 57, 58 HFD also promotes the transition of NAFL to NASH with severe fibrosis, by aggravating metabolic complications in these mice. However, the effect of diet-induced NAFL to NASH transition in these mice depends on the strain. Both, foz/foz C57BL6/J mice and foz/foz BALB/c mice gained weight when fed with HFD, but NAFLD-related liver fibrosis was more severe in foz/foz C57BL6/J mice than in foz/foz BALB/c mice. 59, 60 The other genetic animal models used in the study of NASH include sterol regulatory elementbinding protein 1 (SREBP1-c) transgenic mice, KK-Ay/a mice, peroxisome proliferator-activated receptor a (PPARa) null mice, methionine adenosyl transferase (MAT1A) null mice, phosphatase and tensin homolog (PTEN) null mice and acylcoenzyme A oxidase (AOX) null mice.
11,61-66
Animal models to study the effect of specific genes to protect against NASH Another potential application of animal models is to study the relevance of specific genes for the development and progression of NASH. Macrophages are a special type of immune cell. They are large, phagocytic in nature, and found in almost all types of tissue or as mobile white blood cells, especially at sites of infection during an innate-immune response. They are the primary mediators of the sterile inflammatory response in NASH. Proinflammatory macrophages are recruited to the liver during the NAFL to NASH transition from hematopoietic stem cell derived myeloid lineage cells rather than yolk sac-derived resident hepatic macrophages (Kupffer cells or liver macrophages). 67, 68 These cells are proinflammatory in conditions of obesity, insulin resistance and fatty liver, and secrete a number of inflammatory cytokines, such as monocyte chemotactic protein 1 (MCP-1), TNF-a, IL-10, IL-6. MCP-1 is a major chemokine critical for recruiting myeloid cells to the liver via its receptor, chemokine (C-C motif) receptor 2 (CCR-2). This CCR-2 is known to be highly expressed in hepatic macrophages during NAFL, NASH and HCC. 67, 69, 70 There are many animal studies showing the importance of MCP-1-CCR2 signaling in NASH pathogenesis. 67, 69 The CCR-2 (Ccr2 À/À ) deficient mice are protected from the development of hepatic steatosis, inflammation, macrophage infiltration and fibrosis. 69 Mice lacking toll like receptor (TLR)-4, TLR-9 or myeloid cell differentiation (MyD) 88 all demonstrate reduced hepatic macrophage accumulation. Interestingly, these receptors also depend on MCP-1 and CCR-2 signaling for their function. 71 Similarly, several TLRs have been implicated in NASH and the significance of these receptors has been established with the use of an apolipoprotein E knockout mouse model and mice deficient in TLR-9, interleukin 1 receptor, TLR-4 and its co-receptor myeloid differentiation protein 2 (MD-2). 72, 73, 11 In addition, Cjun N-terminal kinase (JNK) knockout mice and inflammasome (Caspase 1, NOD-like receptors [NLR] proteins) deficient mice have demonstrated the significance of inflammatory signaling in the pathogenesis of NASH.
In summary, many advances have been made in the development of preclinical models for NAFLD, providing valuable insight into disease pathogenesis. However, only a few models recapitulate the key elements needed to be representative of human disease. Additionally, there are no published data indicating that the efficacy of a drug in a given model consistently translates into efficacy in humans and vice versa. It is therefore important to be cognizant of the boundaries within which data from animal models must be interpreted, so that the findings from such models are effectively translated into improved therapeutics for humans.
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